Reported 18 days ago
Kenvue, the maker of Tylenol, has faced mounting challenges this year due to claims linking the painkiller to autism, exacerbated by comments from former President Trump advising against its use. The company, under pressure from activist investors and management changes, is considering a strategic review that may include a sale or spin-off of its struggling beauty division. However, the ongoing legal complications regarding Tylenol could deter potential buyers, seriously affecting Kenvue's market value, currently estimated at around $30 billion.
Source: YAHOO